Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine for treatment of residual neurological deficits in CIDP patients on immunoglobulin therapy
2020-002438-34Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dalfampridine in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by University Hospital Odense. Primary endpoints: Time to perform six-spot-step test and Time to perform nine-hole-pegboard test. Started Jun 2020; status: completed.
02
Drugs
dalfampridine
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2020-002438-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002438-34.